HEMI-AMINAL ETHERS AND THIOETHERS OF N-ALKENYL CYCLIC COMPOUNDS
    1.
    发明申请
    HEMI-AMINAL ETHERS AND THIOETHERS OF N-ALKENYL CYCLIC COMPOUNDS 审中-公开
    N-烷基环化合物的氨基甲酸酯及其衍生物

    公开(公告)号:WO2014116560A1

    公开(公告)日:2014-07-31

    申请号:PCT/US2014/012254

    申请日:2014-01-21

    Abstract: Described herein are hemi-aminal ethers and thioethers of N -alkenyl cyclic compounds that may be produced through a reaction comprising: (A) at least one first reactant represented by a structure (I), wherein X is a functionalized or unfunctionalized C 1 -C 5 alkylene group optionally having one or more heteroatoms, and each R 1 , R 2 , and R 3 is independently selected from the group consisting of hydrogen and functionalized and unfunctionalized alkyl groups optionally having one or more heteroatoms, and (B) at least one second reactant having at least one hydroxyl moiety or thiol moiety. The hemi-aminal ethers and thioethers of N -alkenyl cyclic compounds may comprise a polymerizable moiety, in which case they may be left as-is or used to create homopolymers or non-homopolymers, or they may not comprise a polymerizable moiety. A wide variety of formulations may be created using the hemi-aminal ethers and thioethers of N -alkenyl cyclic compounds, including personal care, oilfield, and construction formulations.

    Abstract translation: 本文描述的是可通过以下反应产生的N-烯基环状化合物的半缩醛醚和硫醚:包括:(A)由结构(I)表示的至少一种第一反应物,其中X是官能化或未官能化的C1-C5 任选具有一个或多个杂原子的亚烷基,并且每个R 1,R 2和R 3独立地选自氢和任选具有一个或多个杂原子的官能化和未官能化的烷基,和(B)至少一种第二反应物,其具有 至少一个羟基部分或硫醇部分。 N-烯基环状化合物的半芳基醚和硫醚可以包含可聚合部分,在这种情况下,它们可以原样保留或用于产生均聚物或非均聚物,或者它们可以不包含可聚合部分。 可以使用N-烯基环状化合物的半缩醛醚和硫醚,包括个人护理,油田和施工制剂,可以产生多种制剂。

    コンフォメーション病医薬組成物
    4.
    发明申请
    コンフォメーション病医薬組成物 审中-公开
    用于配合疾病的药物组合物

    公开(公告)号:WO2007123187A1

    公开(公告)日:2007-11-01

    申请号:PCT/JP2007/058566

    申请日:2007-04-20

    Inventor: 堂浦 克美

    CPC classification number: C08B11/02 A61K31/717 C08B11/08 C08B11/12

    Abstract: Disclosed is a pharmaceutical composition having a prophylactic or therapeutic effect on a conformational disease such as Alzheimer's disease, prion disease and amyloidosis. The pharmaceutical composition comprises, as an active ingredient, at least one cellulose ether selected from a cellulose ether having a constitutional unit represented by the general formula (1) shown below, an alkali metal salt of the cellulose ether, an aliphatic acid ester of the cellulose ether, and a mixture thereof. (1) wherein at least one of R's is selected from CH 3 , C 2 H 5 , CH 2 CH 2 OH, CH 2 CH(OH)CH 3 and CH 2 COOM, and the others are independently represent H; and M is selected from H, Na, K and Ca.

    Abstract translation: 公开了对构象疾病如阿尔茨海默氏病,朊病毒病和淀粉样变性疾病具有预防或治疗作用的药物组合物。 所述药物组合物含有至少一种纤维素醚,所述纤维素醚选自具有下述通式(1)所示结构单元的纤维素醚,所述纤维素醚的碱金属盐,所述纤维素醚的脂肪酸酯 纤维素醚及其混合物。 (1)其中R中的至少一个选自CH 3,C 2 H 5,CH 2, CH 2 OH,CH 2 CH(OH)CH 3和CH 2 COOM,其它独立地为 代表H; M选自H,Na,K和Ca。

    RAW COTTON LINTERS COMPOSITION, METHOD OF MAKING AND USES THEREOF
    10.
    发明申请
    RAW COTTON LINTERS COMPOSITION, METHOD OF MAKING AND USES THEREOF 审中-公开
    原始棉线组合物,其制备方法及其用途

    公开(公告)号:WO2006107294A1

    公开(公告)日:2006-10-12

    申请号:PCT/US2005/011373

    申请日:2005-04-04

    CPC classification number: C08B11/193 C08B1/00 C08B11/00 C08B11/02 C08B11/04

    Abstract: A composition of a loose mass of comminuted raw cotton linter fibers has a bulk density of at least 8 g/100 ml and at least 50 % of the fibers in the mass passes through a US standard sieve size #10 (2 mm opening). This composition is made by obtaining a loose mass of first cut, second cut, third cut, or mill runs raw cotton linters or mixtures thereof and comminuting the loose mass of raw cotton linters to a size wherein at least 50 % pass through a US standard sieve size #10 (2 mm opening). This composition is used to make cellulose ether derivatives.

    Abstract translation: 粉碎的原棉短绒纤维的松散质量的组合物的堆积密度为至少8g / 100ml,并且质量中至少50%的纤维通过美国标准筛号#10(2mm开口)。 该组合物通过获得松散质量的第一切割,第二切割,第三切割或粗轧原棉短绒或其混合物制成,并将松散的原棉短绒粉碎成至少50%通过美国标准的尺寸 筛子尺寸#10(2mm开口)。 该组合物用于制备纤维素醚衍生物。

Patent Agency Ranking